Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2020-04-30 Regulatory Filings
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
CHMP Issues Positive Opinion Recommending Subcutaneous Formulation of Daratumumab for the Treatment of Patients with Multiple Myeloma
Regulatory Filings Classification · 95% confidence The document is a 'Company Announcement' issued by Genmab regarding a regulatory milestone (CHMP Positive Opinion). It is a standard corporate press release announcing a specific business development event rather than a periodic financial report, proxy statement, or audit. Under the provided filing definitions, general regulatory announcements that do not fit into specific categories like M&A or dividends are classified as RNS (Regulatory Filings).
2020-04-30 English
Regulatory Filings 2020
Regulatory Filings Classification · 100% confidence The document is titled "CHMP Issues Positive Opinion Recommending Subcutaneous Formulation of Daratumumab for the Treatment of Patients with Multiple Myeloma" and is explicitly labeled as a "Company Announcement." It details a regulatory decision (Positive Opinion from CHMP/EMA) regarding a pharmaceutical product. This type of announcement, which communicates a specific, non-periodic regulatory or corporate event outcome rather than comprehensive financial results (like 10-K or IR) or a general market update (like RNS), fits best under the general category of Regulatory Filings (RNS) as it is a specific, non-standard announcement that doesn't align with the other defined categories like ER, AR, or CT. Since it is a direct announcement of a regulatory event outcome and not a report itself, RNS is the most appropriate fallback.
2020-04-30 English
6-K
Foreign Filer Report
2020-04-14 English
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2020
Earnings Release Classification · 95% confidence The document is a short company announcement (under 5,000 characters of core text, excluding boilerplate) that reports specific financial highlights (net sales of DARZALEX for Q1 2020) and explicitly includes an 'Attachment' link at the bottom to the full report. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA). Q1 2020
2020-04-14 English
Earnings Release 2020
Earnings Release Classification · 99% confidence The document is titled "Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2020" and explicitly states key financial figures (net sales of USD 937 million) for the first quarter of 2020. This content structure—announcing specific, period-based financial results (Q1 2020) in a concise press release format—aligns perfectly with the definition of an Earnings Release (ER), which covers periodical financial results (key highlights only). It is not a comprehensive Interim Report (IR) or Annual Report (10-K), nor is it merely an announcement of a report (RPA). Q1 2020
2020-04-14 English
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Director's Dealing Classification · 98% confidence The document explicitly states it discloses data of transactions in Genmab A/S shares made by managerial employees and their closely associated persons, referencing Article 19 of Regulation No. 596/2014 (Market Abuse Regulation). This type of filing, detailing insider trading or transactions by management/directors, corresponds directly to the 'Director's Dealing' category. Although it is a 'Company Announcement', the specific content dictates the classification as DIRS, not RNS or RPA, as it is the substance of the filing itself, not just an announcement of a report.
2020-04-01 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.